​
​

Genprex Stock (NASDAQ:GNPX)

RevenueOwnershipFinancialsChart
Genprex by TradingView

Previous Close

$1.36

52W Range

$0.28 - $14.40

50D Avg

$1.05

200D Avg

$2.16

Market Cap

$10.93M

Avg Vol (3M)

$9.43M

Beta

-1.29

Div Yield

-

GNPX Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

21

IPO Date

Mar 29, 2018

Website

GNPX Performance

GNPX Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-30.86M$-23.83M$-19.60M
Net Income$-30.86M$-29.46M$-19.59M
EBITDA$-30.86M$-23.81M$-19.58M
Basic EPS$-22.56$-24.58$-16.64
Diluted EPS$-22.56$-24.58$-16.64

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
GRCLGracell Biotechnologies Inc.
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
RVPHReviva Pharmaceuticals Holdings, Inc.
RNAZTransCode Therapeutics, Inc.
EFTReFFECTOR Therapeutics, Inc.
KODKodiak Sciences Inc.
EYENEyenovia, Inc.
GLSIGreenwich LifeSciences, Inc.
CGTXCognition Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
ELEVElevation Oncology, Inc.